Literature DB >> 34410484

The preproliferative stage in type 2 macular telangiectasia (MacTel type 2).

Ramesh Venkatesh1, Nikitha Gurram Reddy2, Pranjal Mishra2, Arpitha Pereira3, Deepashri Mutalik2, Sameeksha Agrawal2, Abhishek Bhatt2, Naresh Kumar Yadav2, Jay Chhablani4.   

Abstract

PURPOSE: To study clinical and imaging features of various stages of macular telangiectasia (MacTel type 2).
METHODS: In this retrospective study, cases of MacTel type 2 with fluorescein angiography (FA), optical coherence tomography (OCT) and OCT-angiography (OCTA) imaging were included. Based on angiographic perifoveal fluorescence, two groups were formed: group 1: diffuse hyperfluoroscence and group 2: diffuse + focal hyperfluoroscence. Later, based on OCT features, group 2 was subdivided into group 2A: without SRNVM and group 2B: with SRNVM. Clinical, FA, OCT and OCTA features were analysed. Eyes showing conversion to the proliferative stage at final visit were noted.
RESULTS: Ninety-four eyes of 48 patients were included. Group 1 (n = 28) showed diffuse perifoveal hyperfluoroscence, hyperreflective middle retinal layers, absent SRNVM (p = 0.006) on OCT and dilated perifoveal capillaries in deep capillary plexus (DCP) on OCTA. Group 2A (n = 40) showed diffuse + focal perifoveal hyperfluoroscence, hyperreflective middle retinal layers (p = 0.001), hyporeflective outer retina cavities (p = 0.021), absent SRNVM with dilated and bunching perifoveal capillaries (p = 0.004) in DCP. Group 2B (n = 26) showed late diffuse + focal perifoveal hyperfluoroscence, foveal contour irregularity (p = 0.002), retinal pigment clumps (p = 0.015) and SRNVM on OCT with bunching of capillaries in DCP and vessels in outer retina (p = 0.002). Five eyes showed conversion to group 2B at final visit.
CONCLUSION: There exists a distinct disease stage called "preproliferative" MacTel type 2 showing clinical features of non-proliferative disease, diffuse + focal perifoveal hyperfluoroscence on FA, absent SRNVM on OCT and bunching perifoveal capillaries in DCP on OCTA. Its identification is important for suspecting proliferative disease, planning management and follow-up visit accordingly.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Disease stages; MacTel type 2; Macular telangiectasia; Preproliferative stage; Retinal imaging

Mesh:

Year:  2021        PMID: 34410484     DOI: 10.1007/s00417-021-05371-1

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  14 in total

1.  Epiretinal Neovascularization: A Novel OCT Angiography Finding in Macular Telangiectasia Type 2.

Authors:  Apoorva G Ayachit; Lakshmipriya Uday Reddy; Shrinivas Joshi; Guruprasad S Ayachit
Journal:  Ophthalmol Retina       Date:  2019-02-06

2.  Perifoveal müller cell depletion in a case of macular telangiectasia type 2.

Authors:  Michael B Powner; Mark C Gillies; Marina Tretiach; Andrew Scott; Robyn H Guymer; Gregory S Hageman; Marcus Fruttiger
Journal:  Ophthalmology       Date:  2010-08-03       Impact factor: 12.079

3.  Incidence and phenotypical variation of outer retina-associated hyperreflectivity in macular telangiectasia type 2.

Authors:  Stefanie Mueller; Frederic Gunnemann; Kai Rothaus; Marius Book; Henrik Faatz; Alan Bird; Daniel Pauleikhoff
Journal:  Br J Ophthalmol       Date:  2021-01-07       Impact factor: 4.638

4.  Familial asymptomatic macular telangiectasia type 2.

Authors:  Mark C Gillies; Meidong Zhu; Emily Chew; Daniel Barthelmes; Edward Hughes; Haipha Ali; Frank G Holz; Hendrik P N Scholl; Peter Charbel Issa
Journal:  Ophthalmology       Date:  2009-10-07       Impact factor: 12.079

5.  Loss of Müller's cells and photoreceptors in macular telangiectasia type 2.

Authors:  Michael B Powner; Mark C Gillies; Meidong Zhu; Kristis Vevis; Alex P Hunyor; Marcus Fruttiger
Journal:  Ophthalmology       Date:  2013-06-12       Impact factor: 12.079

Review 6.  Idiopathic macular telangiectasia type 2 (idiopathic juxtafoveolar retinal telangiectasis type 2A, Mac Tel 2).

Authors:  Lihteh Wu; Teodoro Evans; J Fernando Arevalo
Journal:  Surv Ophthalmol       Date:  2013 Nov-Dec       Impact factor: 6.048

7.  Non-proliferative type II macular telangiectasia variant with subfoveal detachment: role of anti-VEGF therapy.

Authors:  George J Manayath; Ratnesh Ranjan; C K Nagesha; Venkatapathy Narendran
Journal:  Br J Ophthalmol       Date:  2019-12-02       Impact factor: 4.638

8.  Response to anti-vascular endothelial growth factor of abnormal retinal vascular net in para foveal telangiectasia group II images on optical coherence tomography-angiography.

Authors:  Ketan Saoji; Avinash Pathengay; Jay Chhablani; Bhavik Panchal; Shreyansh Doshi; Merlin Saldanha
Journal:  Indian J Ophthalmol       Date:  2019-01       Impact factor: 1.848

9.  Right-angled vessels in macular telangiectasia type 2.

Authors:  Simone Tzaridis; Tjebo Heeren; Clarissa Mai; Sarah Thiele; Frank G Holz; Peter Charbel Issa; Philipp Herrmann
Journal:  Br J Ophthalmol       Date:  2019-02-26       Impact factor: 4.638

10.  Optical coherence tomographic features of macular telangiectasia type 2: Korean Macular Telangiectasia Type 2 Study-Report No. 1.

Authors:  Young Ho Kim; Yoo-Ri Chung; Jaeryung Oh; Seong-Woo Kim; Christopher Seungkyu Lee; Cheolmin Yun; Boram Lee; So Min Ahn; Eun Young Choi; Sungmin Jang; Kihwang Lee
Journal:  Sci Rep       Date:  2020-10-06       Impact factor: 4.379

View more
  1 in total

Review 1.  Macular Telangiectasia Type 2: A Comprehensive Review.

Authors:  Kiran Chandra Kedarisetti; Raja Narayanan; Michael W Stewart; Nikitha Reddy Gurram; Arshad M Khanani
Journal:  Clin Ophthalmol       Date:  2022-10-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.